Peer-reviewed veterinary case report
Factors that predict long-term survival in dogs with high-grade
By Marconato, Laura et al.·Published in Journal of the American Veterinary Medical Association·2011·Clinica Veterinaria L'Arca, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Predictors of long-term survival in dogs with high-grade multicentric lymphoma.
- Species:
- dog
Plain-English summary
A study looked at 127 dogs diagnosed with high-grade multicentric lymphoma, a serious type of cancer, to see which factors might predict long-term survival. Only 13 of the dogs lived more than two years after their diagnosis, with a median survival time of about 914 days. The dogs that survived longer tended to weigh at least 10 kg, had certain blood values, and did not have prior treatment with corticosteroids. This information could help vets identify which dogs might not survive beyond two years, as many of the dogs that did survive longer had specific health characteristics.
People also search for: dog lymphoma survival rate · high-grade lymphoma in dogs · dog cancer treatment options · long-term survival in dogs with lymphoma
Abstract
OBJECTIVE: To determine factors predicting survival in dogs with high-grade multicentric lymphoma. Design-Retrospective cohort study. Animals-127 dogs with high-grade multicentric lymphoma evaluated at 4 veterinary hospitals from 2000 to 2009. PROCEDURES: Records were reviewed to identify dogs with completely staged high-grade multicentric lymphoma treated with chemotherapy. Data collected included signalment, history, hematologic findings, tumor characteristics, treatment, and outcome. Long-term survival was defined as surviving > 2 years after diagnosis. Variables were analyzed for associations with dogs living > 2 years. RESULTS: Among the 127 enrolled dogs, 13 (10%) survived > 2 years with a median survival time of 914 days (range, 740 to 2,058 days). Survival rates at 3, 4, and 5 years were 4%, 3%, and 1 %, respectively. At diagnosis, 11 of the 13 long-term survivors had a body weight ≥ 10 kg, PCV ≥ 35%, absence of ionized hypercalcemia, centroblastic lymphoma, immunophenotype B, absence of bone marrow involvement, and lymphoma stages I through IV and were not previously treated with corticosteroids. The same combination of factors was present in 26 of 114 (23%) dogs surviving ≤ 2 years, yielding a negative predictive value of 97.8% for long-term survivors. Four of the 6 long-term survivors that died during the study died of another cancer; 3 of them had osteosarcoma. CONCLUSIONS AND CLINICAL RELEVANCE: Absence of the aforementioned combination of variables at diagnosis may help identify dogs with lymphoma that will not survive > 2 years. Other types of neoplasia, in particular osteosarcoma, may develop in long-term-surviving dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21320018/